Sneak preview of the Nordic Life Science Days

 

 

This supersession will focus on a specific field of regenerative medicine, Gene Therapy. The possibility to replace defective genes in a patient’s cells with healthy ones using viral vectors and gene editing technologies, opens the potential to treat or prevent numerous diseases which currently lack successful treatment. Although most gene therapies are still in an experimental stage, several examples have recently been successfully translated into clinical practice and products with regulatory approval. This session will discuss the diverse challenges involved in the translation of gene therapies to clinic and market, and highlight some successful examples.

 

 

The diabetes session will focus on disruptive new solutions and future diabetes treatment options. Special focus will be on recent developments, where closed loop systems and ultrafast acting insulins will be game changers for insulin treated diabetes patients, especially those with unstable blood glucose.

 

 

Some biopharma companies have built pipelines that offer more development opportunities than their resources allow them to pursue. Promising clinical trials may be moved down the priority list and their execution delayed – resulting in decline of asset value against a fixed patent expiration date. One potential solution is to package complementary trials and bring them into collaboration with investors, CROs or other organizations and fund the execution of these trials outside the biopharma company. There are several potential advantages of this approach. But this session will also reflect upon questions like: What would be the primary driving forces for different parties to engage in this type of collaborations? Are there also complications with the phenomenon? How does the excess of promising assets with large biopharma companies affect other parts of the life science ecosystem?

 

 

The session gathers a group of experts with complementary expertise to present and discuss recent approaches in Cancer Immunotherapy. Tremendous scientific progress resulted in real clinical breakthroughs and a growing number of cancers are now successfully treated with immunotherapy. However, many challenges remain and for tackling these collaborations among various disciplines is essential. A set of compact presentations will highlight how players from pharma, biotech and academia advance the field and what we can learn from microbiologists and machine learning experts.

 

 

Many of the service providers in life science R&D have their own research. They provide much more than just an extra pair of hands and they spend high amounts on in house development of their services. With this super session, we will highlight their efforts and importance for the life science ecosystem where many of the companies are small and source for the latest technologies for their research and development.